SUNESIS PHARMACEUTIC (SNSS)

Hier bahnt sich etwas grosses an wies scheint. Ist jemand schon dabei???

[Blocked Image: http://img35.imageshack.us/img35/9377/445194sunesis.jpg]

http://www.google.com/finance?q=NASDAQ:SNSS

SUNESIS PHARMACEUTIC (SNSS)

Aurum wrote:

Quote

Aiaiai die haben gestern gute Phase II Resultate präsentiert... wäre fast bei 1.20 rein... naja man kann nicht überall dabei sein!

ja aber das könnte die Aktie schlechthin werden so ala HGSI!!!!!

wo unglaublich was da gekauft wird.

SUNESIS PHARMACEUTIC (SNSS)

The-Saint wrote:

Quote

Jo das HV ist wirklich gut, die Frage ist ob das nun ein kurzer Runn war und sich das ganze wieder legt weil das ding ging auch kurz auf über 2 USD und hat sich dannach wieder ein wenig gelegt.

Die Frage ist was mit dem Kurs die nächsten paar Wochen passiert wen der Hype vorbei ist es gibt ja nicht gleich neue News vom unternehmen bezüglich Präparaten.

LG Simon

Also im Moment ist die Aktie cool zu handeln. Hoher spread und viel interesse vorhanden, ob das Medikament die Zulassung schafft? Mal sehen...

bleibt auf hot watch.

ps: CYCC heute auch gut gehandelt ebenfalls positive phase II ergebnisse. hab 70$ daran verdient ;):

SUNESIS PHARMACEUTIC (SNSS)

Rebound hier voll im gange gearde bei der 3en Welle angekommen mit unglaublichem Volumen. :lol:

Sunesis Announces Publication of Nonclinical Voreloxin Data

Quote:

Quote

SOUTH SAN FRANCISCO, CA -- (MARKETWIRE) -- 01/14/10 --

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the publication of new nonclinical studies with the Company´s lead drug candidate, voreloxin, in the journal Cancer Chemotherapy and Pharmacology. The results demonstrate voreloxin´s potent cytotoxic activity in human acute leukemia cell lines and in an in vivo model when used alone, and enhanced or synergistic activity when used in combination with cytarabine. Sunesis is currently completing Phase 2 studies of voreloxin as a single-agent or in combination with cytarabine in acute myeloid leukemia (AML) and expects to begin Phase 3 testing in AML later in 2010.

"These data contribute to our growing understanding of voreloxin´s nonclinical profile, and, in keeping with our philosophy of clinical development informed by translational research, are directly relevant to our clinical program," said Judith A. Fox, Ph.D., Vice President of Product and Preclinical Development at Sunesis. "We studied voreloxin alone and in combination with cytarabine in leukemia cell lines, as well as in a mouse model of bone marrow ablation. The additive and synergistic effects of the combination in vitro, coupled with the supra-additive effects of the drugs in vivo, translate directly to our ongoing Phase 2 AML program. Importantly, the effects of voreloxin and the combination regimen on bone marrow were fully reversible, mirroring the treatment paradigm for AML."

Voreloxin, alone and in combination with cytarabine, was evaluated in 3 human acute leukemia cell lines: HL-60 (acute promyelocytic leukemia), MV4-11 (AML with a FLT3 mutation) and CCRF-CEM (acute lymphoblastic leukemia). Voreloxin was active in all the leukemia cell lines, including the AML cell line, which is relatively resistant to cytarabine in vitro. Using a combination index (CI) analysis, voreloxin with cytarabine demonstrated synergistic cytotoxic activity HL-60 and MV4-11 cells, and additive activity in CCRF-CEM cells.

In a series of elegant in vivo studies, a murine model of bone marrow ablation was used to evaluate the activity of voreloxin and cytarabine alone and in combination. Bone marrow cellularity, peripheral white blood cell and platelet counts were monitored to assess the impact of and recovery from the study treatments. Voreloxin alone or in combination with cytarabine caused reversible bone marrow ablation accompanied by profound reductions in peripheral white blood cells that were reversible within one week, consistent with the therapeutic goals of AML treatment. The activity of voreloxin at maximum tolerated dose (MTD) was superior to cytarabine at MTD. In addition, the combination demonstrated supra-additive activity in vivo, with a substantially enhanced, but fully reversible, reduction in bone marrow cellularity as compared to each agent alone.

The Cancer Chemotherapy and Pharmacology article and full, published data set are available online at http://www.springerlink.com/content/n7577n7281832171/.

Display More